The study, led by Timothy Klufas of Bridgeport Hospital and the University of Connecticut Department of Dermatology, together with colleagues at the Icahn School of Medicine at Mount Sinai, Quinnipiac University’s Frank H. Netter MD School of Medicine, and UConn, employed a qualitative research technique called photovoice. Developed in the 1990s by public health researchers Caroline Wang and Mary Ann Burris, photovoice asks participants to photograph aspects of their own lives that illustrate their experiences, then to discuss and interpret those images collectively. The method was originally designed as a participatory needs assessment tool for communities whose voices were rarely heard in policy discussions, and it has since been applied to topics ranging from refugee health to disability advocacy. Its central premise is deceptively simple: people are the experts on their own lives, and images can communicate dimensions of experience that questionnaires and clinical scales routinely miss.

Applying photovoice to hidradenitis suppurativa is a methodologically shrewd choice. The disease’s burden is notoriously difficult to quantify. Objective severity measures such as Hurley stage or the SARTOR score capture the anatomical extent of lesions but say little about pain flares, sleep disruption, wound care routines, or the emotional weight of malodorous drainage. Quality-of-life instruments such as Dermatology Life Quality Index questionnaires compress lived experience into numerical scores that can obscure the texture of daily struggle. Previous systematic reviews, including a 2021 thematic synthesis published in the British Journal of Dermatology, have identified recurring themes among patients, including pain, shame, delayed diagnosis, and frustration with fragmented care, but these syntheses rely on retrospective interviews rather than real-time documentation of daily life.

Photovoice inverts the usual power dynamic of research. Instead of being asked to answer questions formulated by investigators, participants decide what matters. In the context of a stigmatizing disease that affects intimate body regions, this shift carries particular significance. Many patients with hidradenitis suppurativa report years of misdiagnosis, being told their lesions were simple boils or hygiene problems, and a pervasive sense that clinicians underestimate their suffering. By authoring their own visual narratives, patients in the study were able to direct attention to the aspects of the disease that they considered most consequential, whether or not those aspects appear in standard outcome measures.

The technical architecture of the study reflects careful attention to both rigor and ethics. The research received exempt approval from the UConn Health Institutional Review Board under protocol number 25X-256-1, and informed consent was obtained from all participants before each phase of the study through information sheets approved by the University of Connecticut Health Center IRB. Detailed methodology, including the photovoice prompts and analytical framework, is available in supplementary materials deposited in a public Mendeley Data repository, an unusual and commendable degree of transparency for a research letter. The authors report that no external funding was secured for the work, and the investigators declared no competing interests. Study design was led by Klufas, Samir Kamat, and Ksenia Gorbenko, with data collection performed by Klufas and initial analysis and drafting shared among Klufas, Santiago, and Kamat, while Santiago, Albert E Zhou, and Akua Sarfo contributed clinical dermatology insights.

The photovoice approach also has an established pedigree in dermatology specifically. A 2023 study published in the British Journal of Dermatology used the method with people affected by leprosy in Papua, Indonesia, where photographs became advocacy tools that challenged entrenched stigma. That project, titled “The unbreakable journey,” demonstrated that patient-generated imagery could shift public perception and even influence local health communication. The hidradenitis suppurativa study extends this lineage to a disease whose stigma, while less visible to the public, is arguably just as corrosive. Patients frequently describe hiding lesions from partners, family members, and employers, and the resulting social isolation compounds the depression and anxiety that are documented at elevated rates in this population.

What makes visual methods particularly powerful for hidradenitis suppurativa is the disease’s intimate geography. Lesions occur in areas that patients rarely expose and that clinicians may examine only briefly during appointments. A photograph of a carefully arranged wardrobe, a supply of wound dressings, a shower bench, or a car seat cushioned to reduce friction can communicate the logistical architecture of coping in ways that verbal description cannot. The images function as what photovoice practitioners call “shards of light,” illuminating specific moments and objects that anchor broader narratives. When participants then discuss their photographs in facilitated sessions, the collective dialogue generates thematic data that is grounded in concrete, personally chosen evidence rather than abstract prompting.

The findings arrive at a moment of rapid therapeutic progress for the disease. Within the past decade, adalimumab, secukinumab, and other biologics have gained regulatory approval for hidradenitis suppurativa, and clinical trials of additional immunomodulatory agents are expanding the armamentarium. Yet a recurring critique from patient advocates is that trial endpoints and treatment goals often diverge from what patients actually want: less pain, fewer flares, better sleep, and the freedom to plan a life without constant contingency for drainage and dressing changes. A 2024 review in the Journal of the American Academy of Dermatology by Steven Daveluy and Ginette Okoye emphasized that quality of life and the patient journey must be central to care, noting that patients often navigate years of diagnostic delay and fragmented referrals before reaching appropriate treatment. Photovoice data provides precisely the kind of patient-grounded evidence that can help align clinical priorities with lived priorities.

There are also implications for medical education and clinical empathy. Dermatology training emphasizes visual pattern recognition, but typically the images studied are clinical photographs taken by professionals for diagnostic purposes. Patient-generated photography inverts this: the image is not a diagnostic specimen but a testimony. For clinicians, viewing the world through a patient’s camera can be a form of perspective-taking that no lecture on empathy can replicate. Prior photovoice research with Congolese refugee women in the Midwestern United States, published in the journal Health Equity in 2021, showed that longitudinal photovoice combined with interviews could document how participants’ priorities and coping strategies evolved over time, suggesting that the method could similarly track the shifting experience of a relapsing-remitting disease like hidradenitis suppurativa across treatment phases.

The study is not without limitations inherent to its design. As a qualitative research letter, it does not attempt statistical generalization, and the small number of participants typical of photovoice projects means the themes identified cannot be assumed to represent the full diversity of the patient population, which spans differences in disease severity, skin tone, sex, socioeconomic status, and access to care. Photovoice also demands considerable participant commitment, which may select for patients who are already engaged and reflective. Nevertheless, the value of the method lies in depth rather than breadth: it surfaces possibilities and priorities that can then be tested and measured at scale using validated instruments.

The broader significance of the work lies in its demonstration that participatory visual methods deserve a firmer place in dermatology research. As the field moves toward patient-centered outcomes and value-based care, the instruments used to define success must reflect what patients themselves consider success. A photograph, as the study’s title suggests, may indeed be worth a thousand words, but its scientific value is realized only when researchers take the time to listen to those words. By combining a proven community-based methodology with rigorous ethical oversight and transparent data sharing, the investigators have provided a template that other dermatology research groups can adapt for conditions ranging from vitiligo to psoriasis to chronic wounds. For a disease that has historically thrived in silence and shame, the simple act of patients pointing a camera at their own lives and having clinicians and researchers genuinely look may prove to be a quietly transformative form of therapy in its own right.

Subject of Research: Using the photovoice participatory photography method to explore the lived experience of patients with hidradenitis suppurativa

Article Title: “A picture is worth a thousand words”: using photovoice to explore the lived experience of hidradenitis suppurativa patients

Article References: Klufas, T., Kamat, S., Saini, S., Santiago, S., Zhou, A. E., Gorbenko, K., & Sarfo, A. (2026). “A picture is worth a thousand words”: using photovoice to explore the lived experience of hidradenitis suppurativa patients. Archives of Dermatological Research, 318(1), Article 413. https://doi.org/10.1007/s00403-026-04871-6

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04871-6

Keywords: hidradenitis suppurativa, photovoice, dermatology, qualitative research, patient-reported outcomes, quality of life, stigma, participatory research, chronic skin disease, medical humanities, patient experience, skin manifestations

Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin disorder marked by periods of exacerbation and remission. Despite its prevalence, the molecular mechanisms dictating individual disease manifestations and responses to therapy have been notoriously difficult to unravel. This challenge largely stems from the immense heterogeneity of the disease at a cellular and molecular level, compounded by skin’s intricate architecture comprising multiple cell types with distinct transcriptional landscapes. Traditional analyses often focus on candidate genes or limited cell populations, which may overlook critical interactions and subtle transcriptomic signatures essential for understanding disease pathogenesis and predicting treatment outcomes.

The study led by Fukushima-Nomura, Kawasaki, Yashiro, and colleagues applied an unbiased tissue transcriptome profiling methodology that bypasses the selective lens of hypothesis-driven research. By capturing gene expression data across entire skin biopsy samples from patients with varying AD phenotypes, the team amassed a comprehensive genetic atlas that includes both epidermal and dermal compartments. Advanced computational algorithms enabled the deconvolution of data, discerning unique transcriptional patterns associated with diverse clinical features like lesion severity, chronicity, and pruritus intensity. This holistic approach provides a panoramic view of the disease’s molecular ecosystem, unearthing novel biomarkers hitherto obscured by traditional techniques.

One of the most significant revelations of this work is the identification of discrete transcriptomic signatures corresponding to specific skin phenotypes in AD. These include gene clusters linked to barrier dysfunction, immune activation, and epidermal differentiation, which collectively orchestrate the disease’s clinical heterogeneity. For example, certain gene expression profiles correlate strongly with heightened Th2-driven inflammatory pathways, a hallmark of acute flares, whereas others reflect chronic remodeling processes emphasizing immune suppression and fibrosis. This nuanced molecular stratification offers an unprecedented framework to contextualize patient variability, moving beyond the conventional “one-size-fits-all” diagnostic paradigm toward a more individualized understanding.

Perhaps even more transformative is the study’s implications for therapeutic responsiveness. Utilizing transcriptomic data obtained before and after treatment interventions, the researchers pinpointed gene sets predictive of favorable or poor responses to standard AD therapies, including topical corticosteroids and newer biologic agents targeting cytokines like IL-4 and IL-13. These predictive markers could serve as invaluable tools in guiding clinical decision-making, allowing physicians to tailor interventions based on a patient’s unique molecular fingerprint rather than relying solely on symptomatic assessment or trial-and-error approaches. Such precision medicine has the potential to reduce treatment failures, adverse effects, and overall healthcare burdens associated with AD.

Underpinning the success of this research is the integration of cutting-edge next-generation sequencing platforms with rigorous bioinformatics pipelines capable of handling vast datasets with high dimensionality. The team leveraged RNA sequencing at unprecedented depth and resolution, generating quantitative profiles of transcripts expressed in lesional and non-lesional skin. Subsequent normalization, clustering, and pathway enrichment analyses distill complex data into biologically meaningful insights, highlighting both known and novel molecular actors involved in AD pathophysiology. This analytic rigor ensures that the reported biomarkers are robust, reproducible, and clinically relevant.

Moreover, the unbiased design of the study circumvents biases intrinsic to pre-selected gene panels, enabling the discovery of unexpected molecular players that may serve as therapeutic targets or diagnostic indicators. For instance, novel cytokines and chemokines that had not been previously linked to AD emerged from the data—some of which are also implicated in other inflammatory and autoimmune diseases, suggesting overlapping pathogenic threads that may be exploited for cross-disease therapies. This opens exciting translational possibilities that extend well beyond dermatology, potentially informing systemic intervention strategies.

The findings also underscore the critical role of the skin microenvironment in dictating disease trajectory. Tissue transcriptome profiles reveal dynamic crosstalk between keratinocytes, immune cells, fibroblasts, and endothelial cells, mediated through intricate signaling networks. Disruptions to this cellular dialogue appear central to lesion development and persistence, highlighting the importance of targeting microenvironmental factors alongside immune modulation. Future research informed by these insights may develop combinatorial therapies designed to restore homeostasis within the skin’s ecosystem more effectively than monotherapies.

Importantly, the research team took steps to ensure clinical applicability by validating their transcriptomic biomarkers in independent patient cohorts across multiple geographic locations and ethnically diverse populations. This strengthens the generalizability of their findings and enhances the potential for implementation in real-world clinical settings. Efforts to integrate transcriptomic assays into routine dermatological practice could revolutionize disease monitoring, allowing for earlier intervention and adaptive management strategies informed by molecular diagnostics.

Technological advancements underpinning this breakthrough also extend to single-cell RNA sequencing and spatial transcriptomics—techniques anticipated to further refine our understanding of cellular heterogeneity and tissue architecture in AD. Although the current study focused on bulk tissue analysis, future directions aim to resolve gene expression at single-cell resolution within the native spatial context, elucidating cell-specific contributions and interactions with unparalleled granularity. These innovations promise to unveil additional layers of complexity and identify rare but clinically significant cell populations involved in disease progression.

Furthermore, the implications of this study reach into the realm of drug development. Identifying molecular markers predictive of therapeutic response can streamline clinical trials by enriching patient cohorts most likely to benefit from investigational drugs, thus improving efficacy signals and minimizing resource wastage. Pharmaceutical companies may leverage these biomarkers as companion diagnostics, facilitating regulatory approval and personalized prescription. This paradigm shift aligns with broader trends toward precision dermatology and individualized patient care.

From a patient perspective, this research carries hope for enhanced quality of life and more effective disease control. AD significantly impairs physical comfort and psychosocial wellbeing due to persistent itching, visible lesions, and treatment-related side effects. Molecularly guided therapies could reduce flares, minimize adverse reactions, and enable patients to regain confidence in their skin health. Additionally, the approach sets a precedent for addressing other heterogeneous skin disorders where current management remains suboptimal.

In conclusion, Fukushima-Nomura and colleagues have charted a compelling path forward in atopic dermatitis research by harnessing the power of unbiased tissue transcriptomics to decode the complexity of skin phenotypes and therapeutic responses. Their integrative and meticulous methodology establishes a blueprint for deploying advanced omics technologies in dermatology and beyond. As the field moves toward molecularly informed clinical practice, such pioneering work illuminates the possibilities and responsibilities that accompany this new era—transforming not only patient outcomes but also the fundamental paradigms through which we understand human health and disease.

Subject of Research: Atopic dermatitis; tissue transcriptome analysis; skin phenotypes; molecular biomarkers; therapeutic response prediction.

Article Title: An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis.

Article References:
Fukushima-Nomura, A., Kawasaki, H., Yashiro, K. et al. An unbiased tissue transcriptome analysis identifies potential markers for skin phenotypes and therapeutic responses in atopic dermatitis. Nat Commun 16, 4981 (2025). https://doi.org/10.1038/s41467-025-59340-x

Image Credits: AI Generated